Search Results
Oct 16, 2025, 08:00 ET TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
at Week 2 or subsequent infusions. In EQUULEUS, patients receiving combination treatment (n=97) were administered the first 16 mg/kg dose at Week 1 split over two days, ie, 8 mg/kg on Day 1 and Day 2, respectively. The incidence of any grade infusion-related reactions was 42%, with 36% of patients experiencing
More news about: Johnson & Johnson
Oct 16, 2025, 07:02 ET JUST MADE LEADS WITH INNOVATION; ROLLS OUT 21 NEW SKUs AT 2025 INTERNATIONAL FRESH PRODUCE AND FLORAL SHOW (IFPA)
Hydration, made delicious. Stay refreshed the natural way with Just Made's new line of organic Refreshers, crafted with real fruit, 1000mg of natural electrolytes and absolutely nothing artificial. Each vibrant flavor delivers tropical hydration you can feel good about, anytime your body
More news about: Just Made
Oct 16, 2025, 07:00 ET Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025
4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively. Skin CancersIn ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated
More news about: Insmed Incorporated
Oct 15, 2025, 16:30 ET Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region
About Spydia (diazepam)In Japan, Aculys Pharma received marketing approval for Spydia Nasal Spray 5 mg, 7.5 mg, and 10 mg for the treatment of status epilepticus in patients 2 years or older in June 2025. This is the first intranasal anti-seizure medication approved
More news about: Viatris Inc.
Oct 15, 2025, 10:50 ET Alcoholic Hepatitis Treatment Market to Reach $772.7 Million by 2027 in the short term and $1,064.98 Million by 2034 Globally, at 4.7% CAGR: Allied Market Research
market position. For instance, in January 2024, ANI Pharmaceuticals, Inc. announced the launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg. Major Global Key Players -
More news about: Allied Market Research
Oct 15, 2025, 10:33 ET JSPR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
2025, Jasper issued a press release reporting updated data from the BEACON Study. The press release stated that "[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed
More news about: Faruqi & Faruqi, LLP
Oct 15, 2025, 10:30 ET Dental Implant Market Valuation to Reach USD 8.4 Billion by 2033, Growing at a CAGR of 6.8% from 2026 to 2033: - Market Research Intellect
Global Alendronate Market Size By Type (5 mg Tablets, 10 mg Tablets, 35 mg Tablets, 70 mg Tablets), By Application (Postmenopausal Osteoporosis, Men with Osteoporosis), Regional Analysis, And Forecast
More news about: Market Research Intellect
Oct 15, 2025, 10:30 ET Active Pharmaceutical Ingredients (API) Market worth $198.39 billion by 2030 with 6.6% CAGR | MarketsandMarkets™
several advantages over large-molecule or biologic drugs. They can be designed to provide strong therapeutic effects at very small doses, often below 10 mg or even at microgram levels. The reduced quantity requirements, coupled with improvements in chemical manufacturing technologies, make synthetic APIs
More news about: MarketsandMarkets
Oct 15, 2025, 10:24 ET ATYR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
corticosteroid (OCS) dose at week 48, with the OCS dose reducing by an average of 2.79mg for 5.0 mg/kg efzofitimod compared to 3.52 mg for placebo. Complete steroid withdrawal was achieved for 52.6% of patients treated with 5.0 mg/kg efzofitimod versus 40.2% on placebo. After aTyr Pharma
More news about: Faruqi & Faruqi, LLP
Oct 15, 2025, 09:17 ET B. Braun Launches Midazolam in 0.8% Sodium Chloride Injection with Enhanced Safety and Usability Features
launch of Midazolam in 0.8% Sodium Chloride Injection in the U.S. market. The preservative-free injections will be offered in two strengths — 50 mg in 50 mL and 100 mg in 100 mL. Both strengths are packaged in IV bags that are not made with DEHP, PVC or natural rubber latex, placing a priority on patient and
More news about: B. Braun Medical Inc.
Oct 15, 2025, 09:00 ET GC Biopharma Announces Symposium on Clinical and Patient Experience in Primary Immunodeficiency and Poster Presentations on IVIG Manufacturing and Viscosity at the 2025 IgNS Annual Meeting
About ALYGLO®ALYGLO® (immune globulin intravenous, human-stwk) is a glycine-stabilized 10% immunoglobulin G (100 mg/mL) for intravenous infusion, manufactured from pooled human plasma from US donors. The manufacturing process includes multiple steps to reduce the risk
More news about: GC Biopharma USA Inc.
Oct 15, 2025, 08:47 ET Uncle Matt's Organic® Launches First-Ever Organic Yerba Mate Energy Tea
#1 Organic Juice Brand Delivers 100mg of Clean Caffeine in a Delicious, Functional Yerba Mate Tea CLERMONT, Fla., Oct. 15, 2025
More news about: Uncle Matt's Organic
Oct 15, 2025, 08:44 ET New Study Reveals Natural Supplement Supercharges Viagra's Effectiveness Without Added Side Effects
effectiveness. Dr. Brandeis's study evaluated 22 men, with an average age of 55, who took sildenafil 40 mg alone for two nights, followed by two nights of sildenafil 40 mg and two AFFIRM tablets containing L-citrulline, red beet root extract, Panax ginseng, and Muira puama. Men wore the FirmTech
More news about: BrandeisMD Inc.
Oct 15, 2025, 08:33 ET SEOULTECH Researchers Discover Breakthrough Materials for Removing Pharmaceuticals from Wastewater
with the monolayer adsorption effect, where molecules get adsorbed onto the adsorbent surface in a single layer. However, beyond a concentration of 60 mg/L, the uptake rose sharply for both beta-blockers, indicating a multilayer adsorption effect. In multilayer adsorption, molecules stack in multiple layers,
More news about: Seoul National University of Science and Technology (SEOULTECH)
Oct 15, 2025, 08:00 ET Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment
The study found that rapid induction—administration of a single dose of 4-mg oral buprenorphine followed by a same-day SUBLOCADE injection—was well tolerated and led to higher retention at the second injection compared to standard
More news about: Indivior PLC
Oct 15, 2025, 07:30 ET Endo Announces Peyronie's Disease Presentation at the North Central Section of the American Urological Association
today that a presentation related to Peyronie's disease, or PD, and XIAFLEX® (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) will be shared during the North Central Section of the American Urological Association (AUA) annual meeting, taking place October 15-18, 2025.
More news about: Endo USA, Inc.
Oct 15, 2025, 06:45 ET Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
safety of orforglipron 3 mg, 12 mg and 36 mg to dapagliflozin 10 mg in participants with type 2 diabetes and inadequate glycemic control with metformin. The study randomized 962 participants in a 1:1:1:1 ratio to receive either orforglipron 3 mg, 12 mg or 36 mg, or dapagliflozin 10 mg once daily, in addition
More news about: Eli Lilly and Company
Oct 14, 2025, 12:00 ET Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress
7MW3711 in the phase I/II study. Among 54 patients treated at 4.0 mg/kg or above and reaching tumor assessment, 19 partial responses (PRs) or complete responses (CRs) were observed. 7 patients with esophageal cancer (EC) were enrolled at 4.0 mg/kg or above and achieved an objective response rate (ORR) of
More news about: Mabwell
Oct 14, 2025, 09:32 ET iOnctura debuts cambritaxestat (IOA-289) clinical data in patients with pancreatic cancer at ESMO
GnP in patients with previously untreated mPDAC. Sixteen patients received cambritaxestat orally, twice daily at doses of 100 mg (n=4), 200 mg (n=4), 400 mg (n=5) and 800 mg (n=3). GnP was administered by IV infusion, weekly for three weeks of a four-week cycle. The results show no dose-limiting toxicities, and no treatment-emergent adverse events (TEAE)
More news about: iOnctura
Oct 14, 2025, 08:59 ET BIOLASE Showcases Breakthrough YSGG Laser Protocol for Predictable Periodontitis Treatment at AAP 2025
treatment outcomes." BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE MG LLC. For updates and information on BIOLASE and laser dentistry, find BIOLASE online at
More news about: BIOLASE MG LLC
Oct 14, 2025, 08:23 ET PLT Health Solutions Unveils Second Clinical Study on Beverage-Friendly Dynagenix® Muscle+Joint Formula Demonstrating Enhanced Mobility & Rapid Joint Comfort within Five Days
a neutral-tasting, water-soluble form, making it ideal for formulating into contemporary delivery systems. The newest study demonstrated that just 40 mg/day of Dynagenix led to statistically significant improvements in joint comfort, stiffness, and function as early as 5 days after initial supplementation.
More news about: PLT Health Solutions
Oct 14, 2025, 08:00 ET Rivus Pharmaceuticals to Present Clinical Data from Phase 2a M-ACCEL Trial of HU6 in MASH as Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025
NCT05979779) evaluated HU6 at 150 mg, 300 mg, and 450 mg once daily for 26 weeks in adults with MASH. Participants were randomized 2:1:2:2 (placebo:HU6 150:HU6 300:HU6 450). Eligible patients had
More news about: Rivus Pharmaceuticals
Oct 14, 2025, 07:10 ET Final analysis of open-label extension (OLE) study of FINTEPLA® (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy & Behavior
study sites in North America, Europe, and Australia, with a median fenfluramine exposure of 364 days (range: 19–537) and a mean daily dose of 0.4±0.1 mg/kg/day (n=246). Meaningful improvements were seen across the key study endpoints listed below:2
More news about: UCB
Oct 14, 2025, 03:30 ET First patient treated with Leqembi® (lecanemab) in the Nordics
recommended indicated population in the label in the European Union (ApoE ε4 heterozygotes or non-carriers). The treatment group was administered lecanemab 10 mg/kg bi-weekly, with participants allocated in a 1:1 ratio to receive either placebo or lecanemab for 18 months.[7] The
More news about: BioArctic
Oct 14, 2025, 01:54 ET 2025 ACR摘要公布！泰它西普治療干燥綜合征中國Ⅲ期臨床研究數據振奮
ESSDAI較基線的變化：第24周時分別為-4.4（160mg）、-3.0（80mg）和-0.6（安慰劑）；第48周時分別為-4.6（160mg）、-3.2（80mg）和-0.4（安慰劑），顯示系統性疾病活動度的持續、劑量依賴性改善。 ESSPRI較基線的變化：第24周時分別為-1.88（160mg）、-1.31（80mg）和 -0.36（安慰劑）；第48周時分別為-2.56（160mg）、-1.74（80mg）和 -0.41（安慰劑），顯示在口干、疲勞和疼痛方面的持續症狀改善。
More news about: 榮昌生物製藥（煙台）股份有限公司